Acadia Pharmaceuticals | ACAD - 流动负债



金融业
股票价格
USD 20.19
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 3.42B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


流动负债 更改 日
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cara Therapeutics USD 11.26M 216K 2026-03
Corcept Therapeutics USD 153.8M 4.62M 2026-06
Cytokinetics USD 181.43M 17.76M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Incyte USD 1.31B 177.55M 2026-06
J&J USD 55.46B 562M 2026-09
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Prothena USD 11.66M 20.86M 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06